Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.5K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Cancer Therapies02:49

Cancer Therapies

9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RECQ5 mediates pre-rRNA processing in nucleolus.

Nucleic acids research·2025
Same author

RNA 2'-O-methylation promotes persistent R-loop formation and AID-mediated IgH class switch recombination.

BMC biology·2024
Same author

DNA-PK participates in pre-rRNA biogenesis independent of DNA double-strand break repair.

Nucleic acids research·2024
Same author

Editorial: Viral infection, tumor development and host immune response.

Frontiers in cellular and infection microbiology·2023
Same author

ADP-ribosylation of histone variant H2AX promotes base excision repair.

The EMBO journal·2020
Same author

AI26 inhibits the ADP-ribosylhydrolase ARH3 and suppresses DNA damage repair.

The Journal of biological chemistry·2020

Related Experiment Video

Updated: Dec 29, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.1K

Targeting dePARylation for cancer therapy.

Muzaffer Ahmad Kassab1, Lily L Yu2, Xiaochun Yu1

  • 11Department of Cancer Genetics & Epigenetics, Beckman Research Institute, City of Hope, Duarte, CA 91010 USA.

Cell & Bioscience
|February 4, 2020
PubMed
Summary

DePARylation, a process downstream of Poly(ADP-ribosyl)ation (PARylation), is crucial for DNA repair and cancer suppression. Inhibiting dePARylation shows promise for future cancer chemotherapy strategies.

Keywords:
ADP-ribosylationCancer therapyDNA damage responsePARGdePARylation

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Related Experiment Videos

Last Updated: Dec 29, 2025

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

2.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Poly(ADP-ribosyl)ation (PARylation) by PARPs is vital for DNA repair and a target for cancer therapy.
  • PARP inhibitors are FDA-approved for treating certain cancers by inducing apoptosis in tumor cells with DNA repair defects.
  • Emerging research highlights the significant role of dePARylation in DNA damage repair.

Purpose of the Study:

  • To review recent advancements in understanding dePARylation's role in DNA damage repair.
  • To explore the potential of targeting dePARylation for cancer treatment.
  • To discuss the relationship between PARylation and dePARylation in DNA repair pathways.

Main Methods:

  • Literature review of preclinical and clinical studies on dePARylation.
  • Analysis of molecular mechanisms underlying dePARylation in DNA repair.
  • Examination of dePARylation inhibitors in cancer models.

Main Results:

  • DePARylation functions as a downstream event in the PARylation pathway during DNA repair.
  • Several dePARylation inhibitors have been developed and evaluated in preclinical cancer studies.
  • DePARylation plays a critical role in DNA damage response and cancer suppression.

Conclusions:

  • Targeting dePARylation represents a potential novel strategy for cancer chemotherapy.
  • Further research into dePARylation pathways could uncover new therapeutic avenues.
  • DePARylation inhibitors may offer a complementary or alternative approach to PARP inhibitors in oncology.